Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy
Vaccines · 10.05.2023 · 11 (5) · 968
DOI: 10.3390/vaccines11050968 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 10.05.2023. Verfasst von Yingyu He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hubei Province, Open Foundation of Hubei Province Key Laboratory.
Abstract (Originalsprache)
For SARS-CoV-2 mutants, the effectiveness of the COVID-19 vaccines is still controversial. In this study, we aimed to investigate the clinical characteristics of Omicron-infected patients who completed primary immunization and booster immunization, respectively, during the rapid propagation of the Omicron variant in China. A total of 932 patients with confirmed SARS-CoV-2 infection from 18 December 2022 to 1 January 2023 were included in this survey by filling out questionnaires online. The enrolled patients were divided into the primary immunization group and the booster immunization group according to their vaccination status. During the whole course of disease, the most frequent symptoms were fever (90.6%), cough (84.3%), weakness (77.4%), headache and dizziness (76.1%), and myalgia (73.9%). Nearly 90% of the patients had symptoms lasting for less than 10 days, and 39.8% of the patients ended the course of the disease in 4–6 days. A total of 58.8% of these patients had a fever with a maximum body temperature of over 38.5 °C. Moreover, 61.4% of the patients had a fever that lasted less than 2 days. There were no obvious differences in initial symptoms, cardinal symptoms, symptom duration time, maximum body temperature, and fever duration time between the two groups of patients. In addition, no significant difference was found in the positive or negative conversion time of SARS-CoV-2 antigen/nucleic acid between the two groups of patients. For mild patients with Omicron breakthrough infection, enhanced immunization has no significant impact on the clinical performance and duration of viral infection compared with primary immunization. The reasons behind the different clinical manifestations of patients with mild symptoms after the breakthrough infection of the Omicron strain are still worth further research. Heterologous vaccination may be a better strategy for enhanced immunization, which can help improve the immune protection ability of the population. Further research should be carried out on vaccines against mutant strains and spectral anti-COVID-19 vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hubei Key Laboratory of Central Nervous System Tumor and Intervention, Wuhan 430070, China.
- Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China.
- Department of Anesthesiology, General Hospital of Central Theater Command of the PLA, Wuhan 430070, China.
ORCID-Profile: Lei Liu
Förderung
- Natural Science Foundation of Hubei Province
- Open Foundation of Hubei Province Key Laboratory
Zitieren
APA
He, Y., Zhang, F., Liu, Y., Xiong, Z., Zheng, S., Liu, W., & Liu, L. (2023). Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy. Vaccines, 11(5), 968. https://doi.org/10.3390/vaccines11050968
Vancouver
He Y, Zhang F, Liu Y, Xiong Z, Zheng S, Liu W, et al. Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy. Vaccines. 2023;11(5):968. doi:10.3390/vaccines11050968
BibTeX
@article{He2023,
author = {He, Yingyu and Zhang, Fang and Liu, Yan and Xiong, Zhou and Zheng, Shangen and Liu, Wanbing and Liu, Lei},
title = {Clinical Characteristics of Mild Patients with Breakthrough Infection of Omicron Variant in China after Relaxing the Dynamic Zero COVID-19 Policy},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {5},
pages = {968},
doi = {10.3390/vaccines11050968}
}
EUVIMED